Ferrous bisglycinate may prevent iron deficiency in pregnant women

December 26, 2013

A study published in the Journal of Perinatal Medicine shows that a low dose of ferrous bisglycinate (Aminojern, a product containing Albion’s Ferrochel) may be equivalent to a higher dose of ferrous salt with regard to hematological and iron status when used by expectant women. This finding is important for the prevention of iron deficiency and iron deficiency anemia that often coincides with pregnancy.

One of the greatest challenges for pregnant women is maintaining adequate iron levels from conception and throughout gestation. Iron is critical for maintaining a woman’s red iron cell stores and to properly support development of a fetus. With the bioavailability of different iron forms varying so greatly and the preference for lower dose iron supplementation gaining acceptance, the researchers sought a comparison of different iron forms and doses.

In this peer-reviewed study, ferrous bisglycinate was taken by 80 Danish pregnant women throughout their pregnancy with measurements taken at 15–19, 27–29, and 36–37 weeks. Women were assigned to either a group that took a 25 mg dose of a ferrous bisglycinate elemental iron per day or a control group using a 50 mg dose of ferrous sulfate elemental iron per day for the designated time period.

The researchers found that participants who received the low dose ferrous bisglycinate benefitted equally to that of the control group with less gastrointestinal complaints. In addition, the newborn weight for the ferrous bisglycinate group was slightly higher than the control group.

Conclusions from the study suggest that adequate prevention of iron deficiency or iron deficiency anemia can be achieved using a low dose of ferrous iron from 15–19 weeks of gestation with appreciable side effects such as lower gastrointestinal distress and healthier baby birth weights. These findings are very important in women with a preference or greater tolerance for a lower dose of iron.